[Skip to Navigation]
Sign In
Comment & Response
November 2018

Magnetic Resonance Imaging–Based Prediction of Prostate Cancer Risk—Reply

Author Affiliations
  • 1National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 2Division of Cancer Treatment and Diagnosis: Biometric Research Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland
  • 3National Cancer Institute, Bethesda, Maryland
JAMA Oncol. 2018;4(11):1625. doi:10.1001/jamaoncol.2018.4234

In Reply We thank Dr Bianchi and colleagues for reiterating the importance of external validation for any prediction tool. Decision support tools such as clinical nomograms are important components of individualized decision making and patient care. Currently, many nomograms are available for different clinical scenarios. Decision making in the prebiopsy setting is of utmost importance because suboptimal decisions can lead to unnecessary biopsies and ultimately overtreatment. Patients with clinically significant prostate cancer, however, need to undergo a biopsy procedure and receive treatment according to their risk profile.

Add or change institution